Jagsonpal Pharmaceuticals Limited — Q3 FY26 earnings call

Call held 22 Jan 2026

Management summary

Jagsonpal Pharmaceuticals Limited reported a flattish Q3 FY26 performance with revenue at INR 73 crores, below expectations due to market headwinds and internal recalibration efforts. However, PAT grew 10% YoY to INR 12.5 crores, and the company generated INR 15.2 crores in free cash, bringing the balance to INR 176 crores. For the nine-month period, revenue grew 6% YoY to INR 223 crores, with PAT increasing 12.5% to INR 35.9 crores, and management anticipates double-digit growth from Q4 FY26 onwards.

Highlights

  • PAT grew by 10% YoY to INR 12.5 crores in Q3 FY26, with PAT margins improving by 180 bps to 17.1%.

  • EBITDA margin stood at 22.7% in Q3 FY26, reflecting operational resilience.

  • For the nine-month period, revenue grew 6% YoY to INR 223 crores, and PAT increased 12.5% YoY to INR 35.9 crores.

  • Free cash balance reached INR 176 crores, with an increase of INR 15.2 crores during the quarter.

  • Management expects growth acceleration to double digits from Q4 FY26, aiming for 50% more than industry growth in the short term.

Concerns

  • Q3 FY26 performance was 'at best flattish' and below internal expectations, as well as relative to the broader Indian pharmaceutical market.

  • The company faced headwinds from its RPM market growing at less than half the overall IPM growth.

  • Near-term disruption and elevated attrition occurred due to a deliberate recalibration of field operations and strategic review.

  • An additional past service cost of INR 2.1 crores was provided as a one-time exceptional item due to the new labor code.

Key financials

2 periods

Headline

  • Free Cash Balance
    ₹176 Cr

Q3 FY26

  • Revenue
    ₹73 Cr
  • EBITDA
    ₹16.7 Cr
  • EBITDA Margin
    22.7%
  • PAT
    ₹12.5 Cr
    YoY +10%
  • PAT Margin
    17.1%

What they filed

Q1 FY27: revenue up 7.9%, net profit up 18.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue75 74 59 76 74 −1%73 −1%64 +8%82 +8%
EBITDA16 16 9 14 16 +0%16 +0%11 +22%17 +21%
Net profit11 32 7 11 13 +18%11 −66%9 +29%13 +18%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • M&A Yash Pharma Acquisition · Integrated

    Successfully demonstrated ability to create value; contributing more than expected to growth; expanding portfolio into speciality mix.

    Assets (intangibles, trademarks) from the acquisition are causing increased depreciation in the current period.

    We did one, Yash Pharma, and have successfully demonstrated our ability to create value out of it. We continue to be on a lookout, but we cannot put in a time frame to it. Having said that, if we are unable to use our cash efficiently, we would rather return it to the shareholders in the right format. / Yes, that's correct. Depreciation has largely moved up because of, if you would have seen our balance sheet, there is an acquisition which we had done last year, Yash Pharma, and the assets are largely comprised of intangibles, trademarks and all. And because of that, those are getting depreciated over the period, and hence the depreciation line has gone.
  • M&A New Acquisitions Acquisition · Announced

    To deploy capital in a meaningful way, be EBITDA accretive, and bring value to shareholders.

    Currently, assets are highly priced, making it challenging to find accretive deals.

    We continue to be on a lookout, but we cannot put in a time frame to it. / Yes, I mean both the options are on the table. So, we will obviously deploy capital in the most meaningful way which is EBITDA accretive eventually. And also, we are seriously looking at some of the good acquisition candidates. Currently, the assets are very highly priced. So, we are looking at something which will bring value to the shareholders.
  • Liquidity Cash ₹176 Cr Free cash balance increased by INR 15.2 crores during the quarter, reflecting strong operational discipline.
    Our free cash balance now stands at INR176 crores, reflecting an increase of INR15.2 crores in the quarter, again reflecting our strong operational discipline.

Guidance & targets

Growth

  • Growth Acceleration Growth · Q4 FY26 · High confidence double digits
    As I mentioned earlier, we are confident of a growth acceleration to double digits from Q4 itself.

    — Manish Gupta

  • Long-term Organic Growth Growth · long-term · High confidence double digits

    Previously 12-14% → double digits

    Yes, Neelam. So, this is what we are looking at, if there are no any macro changes or external changes happening, we expect the growth to be into double digits.

    — Amrut Medhekar

  • Short-term Growth vs Industry Growth · short term · High confidence 50% more than industry growth
    100%, even better. Our idea, Sajal, at least what I am aiming in the short term is 50% more than the industry growth.

    — Amrut Medhekar

Product Launches

  • High Growth Product Launches Product Launches · end of H1 in the coming financial year · Medium confidence should happen
    But as we grow organically, we are also looking at some product launches which are into high growth territory with a better yield per patient. And hopefully that should happen somewhere at the end of H1 in the coming financial year.

    — Amrut Medhekar

Volume Growth

  • Volume Growth & New Products Contribution Volume Growth · going forward · Medium confidence increase
    We expect that we will be able to increase our volume growth going forward as well as contribution from the new products.

    — Amrut Medhekar

Salesforce Productivity

  • Productivity-driven Growth Salesforce Productivity · soon enough · Medium confidence higher double digits
    And once we reach there, actually our growth will be automatically driven towards higher double digits which we are trying to do.

    — Amrut Medhekar

SKU Rationalization

  • Revenue Impact from SKU Rationalization SKU Rationalization · High confidence 1.5-2% of top line
    In terms of revenue, I won't be having an off-the-cuff number, but it will be a small number, maybe around one and a half to two percentage, of the value of the top line.

    — Amrut Medhekar

What to watch in Q4 FY26

Q4 FY26 Revenue Growth

next quarter
Current Flattish in Q3 FY26
Target Double-digit growth

Why it matters

Management has guided for a significant acceleration in growth from Q4 FY26.

As I mentioned earlier, we are confident of a growth acceleration to double digits from Q4 itself.

Risks & concerns

  • Flattish Q3 Performance & Market Headwinds

    medium

    Q3 performance was below expectations due to RPM market growing slower than IPM and internal recalibration efforts.

    Management acknowledged

  • Near-term Disruption from Internal Recalibration

    medium

    Strategic repositioning of brand teams and field operations led to some near-term disruption and elevated attrition.

    Management acknowledged

  • High Asset Prices for M&A

    medium

    Currently, acquisition targets are highly priced, making it challenging to find accretive deals that bring value to shareholders.

    Management acknowledged

  • Muted Volume Growth in Industry

    medium

    Industry volume growth has stayed muted (1-2%), influenced by government spending impacting private practice and increased use of combination brands.

    Management acknowledged

Q&A highlights

7 direct
Impact of New Labor Code Direct
I don't think it will be very different from how we have handled it. Clearly, there are guidelines around it. It is effective from 21st November, but the state rules of notifications are yet to happen. There will be some restructuring of salaries involved at all levels. But having said that, there will be some one-time hit as we have taken.

Clarifies the financial impact (one-time hit of INR 2.1 crores) and operational adjustments due to the new labor code, with management welcoming the move.

Asked by Deepesh J Sancheti

Growth Performance and Future Outlook Partial
It's a mixed bag of performance. Obviously, as Manish has said in his opening remarks, the growth is not as per our own expectations. So, there's a lot of scope for improvement for us to do. And that's what we are on the job to do that.

Acknowledges that current growth is below expectations but expresses commitment to improvement and beating market growth soon, indicating a focus on internal strategies.

Asked by Deepesh J Sancheti

Long-term Organic Growth Target Direct
Yes, Neelam. So, this is what we are looking at, if there are no any macro changes or external changes happening, we expect the growth to be into double digits.

Reaffirms the company's long-term aspiration for double-digit organic growth, providing clarity on future expectations.

Asked by Neelam Punjabi

Yash Pharma Acquisition Performance Direct
We are essentially looking at the past two years since the acquisition has happened. The team has really worked very hard. And today, it is contributing more than the expected lines towards the growth. And also, we are looking at future further expansion of the portfolio into the speciality mix.

Provides an update on a key past acquisition, indicating successful integration and better-than-expected contribution to growth, with plans for further portfolio expansion.

Asked by Neelam Punjabi

Cash Utilization and Capital Allocation Strategy Direct
Yes, Sajal, we are always seriously looking at something. But the capital market is not supportive from an M&A perspective. Obviously, everyone gets much better valuation in the capital market than what a strategic buyer can afford. So clearly, M&A is a very strong intent at our end, but a disciplined M&A which is accretive for our shareholders and not dilutive. So that's very, very important for us. Market has not been supportive in terms of cost or price of acquisition.

Explains the company's approach to its growing cash balance, prioritizing accretive M&A but also considering returning cash to shareholders if suitable opportunities are not found due to high asset valuations.

Asked by Sajal Kapoor

Increase in Depreciation Direct
Yes, that's correct. Depreciation has largely moved up because of, if you would have seen our balance sheet, there is an acquisition which we had done last year, Yash Pharma, and the assets are largely comprised of intangibles, trademarks and all. And because of that, those are getting depreciated over the period, and hence the depreciation line has gone.

Clarifies the reason for the significant increase in depreciation, linking it directly to the intangible assets acquired through the Yash Pharma deal, which is crucial for understanding the P&L impact.

Asked by Sajal Kapoor

Reasons for Lower Growth in Recent Quarters Direct
Dheeresh, I think Amrut would like, I mean, we have two consecutive quarters of slow growth. One was certainly impacted by GST as I covered in my opening remarks. And the second one, again, or the current one, has been lower than expectations, our own worst expectations, partly driven by, again, internal factors because we have, I mean, with Amrut joining us, he has initiated certain critical actions which are going to be, which, I mean, kind of impacted growth for short-term but with a long-term intent of course correcting in terms of driving long-term growth.

Provides a detailed explanation for the recent subdued growth, attributing it to both external factors (GST) and internal strategic recalibration, with an expectation of long-term benefits.

Asked by Dheeresh

Impact of SKU Rationalization Direct
In terms of revenue, I won't be having an off-the-cuff number, but it will be a small number, maybe around one and a half to two percentage, of the value of the top line.

Quantifies the revenue impact of the SKU rationalization strategy, indicating a minor top-line reduction in favor of focusing on larger, more profitable brands.

Asked by Dheeresh

2 min read 7 chapters

Detailed narrative

Q3 FY26 Performance Overview

Jagsonpal Pharmaceuticals Limited reported a flattish performance in Q3 FY26, with revenue at INR 73 crores. Despite this, PAT grew by 10% year-on-year to INR 12.5 crores, and PAT margins improved by 180 basis points to 17.1%. EBITDA for the quarter stood at INR 16.7 crores, translating to an EBITDA margin of 22.7%, reflecting operational resilience.

Nine-Month FY26 Performance

For the nine-month period of FY26, the company demonstrated resilient performance with revenue growing 6% year-on-year to INR 223 crores. EBITDA increased by 5% year-on-year to INR 50.3 crores, maintaining margins at 22.6%. PAT for the nine-month period stood at INR 35.9 crores, marking a 12.5% year-on-year growth with margins at 16.1%.

Strategic Recalibration and Leadership Changes

The company underwent a strategic recalibration of its field operations and leadership team, including the appointment of a new COO and CFO. While these changes led to some near-term disruption and elevated attrition, management expects the benefits to start reflecting from Q4 FY26. The overall intent is to improve the long-term growth engine of the company by enhancing commercial effectiveness and team stability.

New Labor Code Impact

Jagsonpal Pharmaceuticals Limited provided for an additional past service cost of INR 2.1 crores as a one-time exceptional item during Q3 FY26, in anticipation of the new labor code. Management clarified that while there will be some restructuring of salaries across all levels, the ongoing impact on employee costs is expected to be very limited. The state rules for the code, effective from November 21, are still pending notification, expected by February or March.

Capital Allocation and M&A Strategy

The company's free cash balance reached INR 176 crores, increasing by INR 15.2 crores in Q3, reflecting strong operational discipline. Management expressed a strong intent for disciplined and accretive M&A, similar to the successful Yash Pharma acquisition. However, they noted that current asset valuations are high, making it challenging to find suitable targets. If cash cannot be efficiently deployed, the company would consider returning it to shareholders.

Industry Trends and Growth Drivers

The Indian pharmaceutical market (IPM) grew at about 8%, primarily driven by 5-5.5% price growth, with muted volume growth. Jagsonpal's relevant market (RPM) grew slower at 3-3.5%. The company expects future growth to be driven 50% by price increases and new product/SKU introductions, with the remaining from volume growth. The portfolio mix is roughly 35-40% acute and the rest semi-chronic.

Salesforce Productivity and SKU Rationalization

Management is actively working to improve salesforce productivity, which is currently below peer group levels, aiming for higher double-digit growth. Efforts include strategic repositioning of brand teams to focus on high-potential brands and optimizing field deployment. The company also rationalized some very small SKUs that were tying up capital, with an estimated revenue impact of 1.5-2% of the top line, to focus on building larger brands.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls